PEOPLE - IsoTis OrthoBiologics makes appointment:
This article was originally published in Clinica
Bone graft substitutes manufacturer, IsoTis OrthoBiologics (Irvine, California), has appointed James Hart to its board of directors. Mr Hart has had a career spanning 20 years in the orthopaedics industry and has previously been president, CEO and director of ArthroCare and vice-president of strategic marketing for Zimmer. IsoTis' international headquarters is in Lausanne, Switzerland.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.